Long-term investment that prioritises sustainable value creation over immediate returns, without the pressure of rigid divestment timelines.
If you have ever heard of investors who enter a company and sell it within three or four years, patient capital is the exact opposite. It is a way of investing that deliberately forgoes rigid exit timescales to focus on what truly matters: building long-term value alongside the business owner.
Patient capital is a type of investment characterised by extended time horizons — typically beyond seven or ten years — and the absence of pressure to generate quick returns. Unlike traditional private equity funds, which operate with closed-end vehicles of limited life (usually ten years with a possible extension), patient capital investors do not have a clock ticking against them.
This type of capital typically comes from family offices, foundations, sovereign wealth funds, or balance-sheet investors managing their own wealth. Because they do not need to return money to external participants by a fixed date, they can afford to wait for value to materialise organically.
In practice, this translates into fundamentally different investment decisions. A patient investor can support a company through its digital transformation, finance the opening of new markets, or wait for the optimal moment for a bolt-on acquisition — without the urgency of completing an exit to satisfy a fund calendar.
At Blue Mountain, patient capital is at the core of our investment philosophy. We understand that the best companies in the Spanish mid-market are not built or transformed in three years. They require time, trust, and a partner who thinks in decades, not quarters.
For a business owner evaluating who to sell to — or who to partner with for growth — the nature of the capital coming in is as important as the size of the cheque.
When the buyer operates with patient capital, the practical consequences are immediate:
For the seller, working with a patient capital investor significantly reduces the risk that their business legacy will be dismantled or managed with a short-term mindset after the deal. For employees, suppliers, and customers, it means continuity and stability.
The fundamental difference lies in the structure of the investment vehicle:
| Aspect | Traditional private equity | Patient capital |
|---|---|---|
| Investment horizon | 3-5 years (10-year fund) | 7-15+ years or indefinite |
| Exit pressure | High (fund calendar) | Low or non-existent |
| Source of capital | Institutional investors (LPs) | Own balance sheet, family office |
| Leverage | Typically high (LBO) | Moderate or low |
| Objective | Maximise IRR within a fixed term | Maximise absolute value over the long term |
This does not mean patient capital is less demanding. On the contrary: by committing to longer timescales, the patient investor needs deeper conviction about the quality of the business and the management team. Due diligence is, if anything, more thorough, because the relationship will last longer.
Imagine a family-owned logistics company in eastern Spain with 25 million euros in revenue. The founder, aged 62, wants to step back gradually but has no successor within the family. Two offers are on the table:
Option A: Private equity fund. It offers an attractive valuation — 7x EBITDA — but with an aggressive value plan: optimise margins, complete two bolt-on acquisitions, and sell to an industrial buyer within four years. The founder exits entirely in year two.
Option B: Family office with patient capital. It offers a slightly lower valuation — 6.5x EBITDA — but with a five-year transition plan in which the founder remains involved as non-executive chairman. There is no defined exit date. The goal is to double revenue within eight years by capitalising on the digitalisation of the sector.
The founder chooses Option B. Why? Because his priorities are not exclusively financial. He cares that his 180 employees keep their jobs, that the company continues operating from its home region, and that his name does not disappear from the door the following year. Patient capital allows him to achieve all of this without forgoing an economically sound transaction.
Patient capital is especially well suited in the following situations:
Not necessarily. While the IRR (internal rate of return) may be lower on an annualised basis, the multiple on invested capital (MOIC) tends to be higher. An investor who achieves 4x their investment over twelve years generates more absolute value than one who achieves 2.5x in four years, even though the latter’s IRR is technically higher. Moreover, by avoiding repeated transaction costs (buying, selling, buying again), patient capital is more efficient.
The key is in the structure. Ask directly: Where does the capital come from? Are there repayment commitments to third parties? What is the life of the investment vehicle? If the capital comes from a closed-end fund with a maturity date, it is not genuine patient capital, no matter how it is presented. Family offices and balance-sheet investors who deploy their own capital are, by definition, more patient than any manager administering other people’s money with repayment deadlines.
Not at all. In fact, it is especially relevant in the mid-market (companies with 3 to 50 million euros in revenue), where transactions often involve founders with a strong emotional bond to the business. In this segment, guarantees about continuity and timelines are frequently the decisive factor in closing a deal — even more so than price.
If you wish to explore a potential collaboration or present an investment opportunity, we invite you to contact us. We guarantee absolute confidentiality in all our conversations.